Citations

Clear

16281 citation(s) found for "Yu, David".

Clinical Significance of Tumor Location for Ureteroscopic Tumor Grading in Upper Tract Urothelial Carcinoma
Katayama, Satoshi , Pradère, Benjamin , Grossmann, Nico C. , Potretzke, Aaron M. , Boorjian, S., Daneshmand, Siamak , Djaladat, Hooman , Sfakianos, John P. , D’Andrea, David , Hayakawa, Nozomi , Heindenreich, Axel, Margulis, Vitaly , Karakiewicz, Pierre I, Nasu, Yasutomo , Shariat, Shahrokh F., Grossman, Nico C , Daneshmand, Siamak , D'Andrea, David , Ghoreifi, Alireza , Pradere, Benjamin , Ghoreifi, Alireza , Mari, Andrea , Khene, Z. , Fujita, Kazutoshi , Heindenreich, Axel, Raman, Jay D. , Roumiguié, M. , Abdollah, Firas , Breda, Alberto , Fontana, Matteo , Rouprêt, Morgan , Karakiewicz, Pierre I., Araki, Motoo , Shariat, Shahrokh F.

Mayo Clinic

Journal of Endourology | September 12, 2024 | Volume: 38 | Issue: 11 | Pages: 1156-1163

10.1089/end.2024.0335 | PMID 39264866 Get It

Background: Although previous literature shows tumor location as a prognostic factor in upper tract urothelial carcinoma (UTUC), there remains uninvestigated regarding the impact of tumor location on grade concordance and discrepancies between ureteroscopic (URS) biopsy and final radical nephroureterectomy (RNU) pathology. Methods: In this international study, we retrospectively reviewed the records of 1,498 patients with UTUC who underwent diagnostic URS with concomitant biopsy followed by RNU between 2005 and 2020. Tumor location was divided into four sections: the calyceal-pelvic system, proximal ureter, middle ureter, and distal ureter. Patients with multifocal tumors were excluded from the study. We performed multiple comparison tests and logistic regression analyses. Results: Overall, 1,154 patients were included; 54.4% of those with low-grade URS biopsies were upgraded on RNU. In the multiple comparison tests, middle ureter tumors exhibited the highest probability of upgrading, meanwhile pelvicalyceal tumors exhibited the lowest probability of upgrading (73.7% vs 48.5%, p = 0.007). Downgrading was comparable across all tumor locations. On multivariate analyses, middle ureteral location was significantly associated with a low probability of grade concordance (odds ratio [OR] 0.59; 95% confidence interval [CI], 0.35–1.00; p = 0.049) and an increased risk of upgrading (OR 2.80; 95% CI, 1.20–6.52; p = 0.017). The discordance did not vary regardless of caliceal location, including the lower calyx. Conclusions: Middle ureteral tumors diagnosed to be low grade had a high probability to be undergraded. Our data can inform providers and their patients regarding the likelihood of undergrading according to tumor location, facilitating patient counseling and shared decision making regarding the choice of kidney sparing vs RNU.
Diagnosis and Treatment of Perioperative Anemia: A Society for Perioperative Assessment and Quality Improvement Collaborative Review
Kumar, Mandeep , Hepner, David L. , Grawe, Erin S., Keshock, Maureen , Khambaty, Maleka , Patel, Manish S. , Sweitzer, BobbieJean, Sweitzer, BobbieJean

Mayo Clinic

Anesthesiology | September 12, 2024 | Volume: 141 | Issue: 5 | Pages: 984-996

10.1097/aln.0000000000005111 | PMID 39264293 Get It

Roadmap to a Global Template for Implementation of Ototoxicity Management for Cancer Treatment
Fernandez, Katharine , Hoetink, Alex E. , Berndtson, Deborah, Clark, Khaya D. , Dreisbach, Laura , Grosnik, Amy, Jamis, Carmen, Lee, John , Liberman, Patrícia Helena Pecora, Milnes, Trisha, Meijer, Annelot J. M. , Ortiz, Candice E., Rooker, Jennessa , Heuvel-Eibrink, Mary M. van den, Brewer, Carmen C. , Poling, Gayla L. , Clark, Khaya , Konrad‐Martin, Dawn , Geller, James I. , Goffi-Gómez, María Valéria Schmidt , Knight, Kristin R. , Lee, David S. , Sanchez, Victoria A , Heuvel‐Eibrink, Mary M. van den

Mayo Clinic

Ear & Hearing | September 12, 2024 | Volume: 46 | Issue: 2 | Pages: 286-297

10.1097/aud.0000000000001592 | PMID 39261989 Get It

Ototoxicity is among the adverse events related to cancer treatment that can have far-reaching consequences and negative impacts on quality-of-life for cancer patients and survivors of all ages. Ototoxicity management (OtoM) comprises the prevention, diagnosis, monitoring, and treatment, including rehabilitation and therapeutic intervention, of individuals who experience hearing loss, tinnitus, or balance/vestibular difficulties following exposures to ototoxic agents, including platinum chemotherapy (cisplatin, carboplatin) and cranial radiation. Despite the well-established physical, socioeconomic, and psychological consequences of hearing and balance dysfunction, there are no widely adopted standards for clinical management of cancer treatment-related ototoxicity. Consensus recommendations and a roadmap are needed to guide development of effective and feasible OtoM programs, direct research efforts, address the needs of caregivers and patients at all stages of cancer care and survivorship. Here we review current evidence and propose near-term to longer-term goals to advance OtoM in five strategic areas: (1) beneficiary awareness, empowerment, and engagement, (2) workforce enhancement, (3) program development, (4) policy, funding, and sustainability, and (5) research and evaluation. The goal is to identify needs and establish a roadmap to guide worldwide adoption of standardized OtoM for cancer treatment and improved outcomes for patients and survivors.
Development of a Breast Cancer Risk Prediction Model Integrating Monogenic, Polygenic, and Epidemiologic Risk
Kalia, Sarah S. , Boddicker, Nicholas , Yadav, Siddhartha , Huang, Hongyan , Na, Jie , Ambrosone, Christine B. , Yao, Song , Haiman, Christopher A. , Chen, Fei , John, Esther M. , Kurian, Allison W. , Guo, Boya , Lindström, Sara , Auer, Paul L. , Taylor, Jack A. , Hodge, James M. , Lori, Adriana , Bodelón, Clara , Vachon, Celine M. , Goldgar, David E. , Nathanson, Katherine L. , Weitzel, Jeffrey N. , Boddicker, Nicholas J , Hu, Chunling , Ambrosone, Christine B , Yao, Song , Haiman, Christopher A , Chen, Fei , John, Esther M , Kurian, Allison W , Guo, Boya , Lindstrom, Sara , Auer, Paul , Lacey, James V. , Neuhausen, Susan L. , Martı́nez, Marı́a Elena , Sandler, Dale P , O'Brien, Katie M , Taylor, Jack A , Teras, Lauren R , Hodge, James M , Lori, Adriana , Bodelon, Clara , Trentham-Dietz, Amy , Burnside, Elizabeth S , Vachon, Celine M. , Winham, Stacey J , Goldgar, David E , Domchek, Susan M , Nathanson, Katherine L , Weitzel, Jeffrey N , Couch, Fergus J. , Kraft, Peter , Yadav, Siddhartha , Na, Jie , Hu, Chunling , Sandler, Dale P. , O’Brien, Katie M. , Teras, Lauren R. , Trentham‐Dietz, Amy , Burnside, Elizabeth S. , Winham, Stacey J. , Domchek, Susan M. , Couch, Fergus J. , Kraft, Peter

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 11, 2024 | Volume: 33 | Issue: 11 | Pages: 1490-1499

10.1158/1055-9965.epi-24-0594 | PMID 39259185 Get It

Abstract Background: Breast cancer has been associated with monogenic, polygenic, and epidemiologic (clinical, reproductive, and lifestyle) risk factors, but studies evaluating the combined effects of these factors have been limited. Methods: We extended previous work in breast cancer risk modeling, incorporating pathogenic variants (PV) in six breast cancer predisposition genes and a 105-SNP polygenic risk score (PRS), to include an epidemiologic risk score (ERS) in a sample of non-Hispanic White women drawn from prospective cohorts and population-based case–control studies, with 23,518 cases and 22,832 controls, from the Cancer Risk Estimates Related to Susceptibility (CARRIERS) Consortium. Results: The model predicts 4.4-fold higher risk of breast cancer for postmenopausal women with no predisposition PV and median PRS, but with the highest versus lowest ERS. Overall, women with CHEK2 PVs had >20% lifetime risk of breast cancer. However, 15.6% of women with CHEK2 PVs and a family history of breast cancer, and 45.1% of women with CHEK2 PVs but without a family history of breast cancer, had low (<20%) predicted lifetime risk and thus were below the threshold for MRI screening. CHEK2 PV carriers at the 10th percentile of the joint distribution of ERS and PRS, without a family history of breast cancer, had a predicted lifetime risk similar to the general population. Conclusions: These results illustrate that an ERS, alone and combined with the PRS, can contribute to clinically relevant risk stratification. Impact: Integrating monogenic, polygenic, and epidemiologic risk factors in breast cancer risk prediction models may inform personalized screening and prevention efforts.
Overview of ADNI MRI
Jack, Clifford R. , Arani, Arvin , Borowski, Bret, Crawford, Karen , DeCarli, Charles , Fletcher, Evan, Fox, Nick C. , Gunter, Jeffrey L. , Ittyerah, Ranjit, Harvey, Danielle , Jahanshad, Neda , Maillard, Pauline , Malone, Ian B., Reyes, Denise A., Thomas, David L. , Thompson, Paul M., Tosun, Duygu , Ward, Chadwick P., Weiner, Michael W., Initiative, Alzheimer's Disease Neuroimaging, DeCarli, Charles , Malone, Ian B. , Borowski, Bret J, Jack, Clifford R , Arani, Arvin , Fox, Nick C , Harvey, Danielle J , Tosun, Duygu , Maillard, Pauline , Cash, David M. , Das, Sandhitsu R. , Nir, Talia M. , Reid, Robert I. , Schwarz, Christopher G. , Senjem, Matthew L. , Thompson, Paul M. , Yushkevich, Paul A. , Initiative, Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | September 11, 2024 | Volume: 20 | Issue: 10 | Pages: 7350-7360

10.1002/alz.14166 | PMID 39258539 Get It

Abstract The magnetic resonance imaging (MRI) Core has been operating since Alzheimer's Disease Neuroimaging Initiative's (ADNI) inception, providing 20 years of data including reliable, multi‐platform standardized protocols, carefully curated image data, and quantitative measures provided by expert investigators. The overarching purposes of the MRI Core include: (1) optimizing and standardizing MRI acquisition methods, which have been adopted by many multicenter studies and trials worldwide and (2) providing curated images and numeric summary values from relevant MRI sequences/contrasts to the scientific community. Over time, ADNI MRI has become increasingly complex. To remain technically current, the ADNI MRI protocol has changed substantially over the past two decades. The ADNI 4 protocol contains nine different imaging types (e.g., three dimensional [3D] T1‐weighted and fluid‐attenuated inversion recovery [FLAIR]). Our view is that the ADNI MRI data are a greatly underutilized resource. The purpose of this paper is to educate the scientific community on ADNI MRI methods and content to promote greater awareness, accessibility, and use. Highlights The MRI Core provides multi‐platform standardized protocols, carefully curated image data, and quantitative analysis by expert groups. The ADNI MRI protocol has undergone major changes over the past two decades to remain technically current. As of April 25, 2024, the following numbers of image series are available: 17,141 3D T1w; 6877 FLAIR; 3140 T2/PD; 6623 GRE; 3237 dMRI; 2846 ASL; 2968 TF‐fMRI; and 2861 HighResHippo (see Table 1 for abbreviations). As of April 25, 2024, the following numbers of quantitative analyses are available: FreeSurfer 10,997; BSI 6120; tensor based morphometry (TBM) and TBM‐SYN 12,019; WMH 9944; dMRI 1913; ASL 925; TF‐fMRI NFQ 2992; and medial temporal subregion volumes 2726 (see Table 4 for abbreviations). ADNI MRI is an underutilized resource that could be more useful to the research community.
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis
Abro, Brooj , Maurer, Matthew J. , Burack, Richard , Chapman, Jennifer R. , Cohen, Jonathon B. , Friedberg, Jonathan W. , Inghirami, Giorgio , Lossos, Izidore S. , Martin, Peter W., McDonnell, Timothy J. , Riska, Shaun M., Flowers, Christopher R. , Burack, W Richard , Cohen, Jonathon B , Inghirami, Giorgio , Link, Brian K , Lossos, Izidore S , Nastoupil, Loretta J , Vega, Francisco , Cerhan, James R , Feldman, Andrew L , Maurer, Matthew , Habermann, Thomas M. , Kahl, Brad S. , Larson, Melissa C. , Link, Brian K. , Martin, Peter, Nastoupil, Loretta J. , Syrbu, Sergei , Vega, Francisco , Vij, Kiran R , Cerhan, James R. , Jaye, David L. , Feldman, Andrew L.

Mayo Clinic

Blood | September 10, 2024 | Volume: 144 | Issue: 19 | Pages: 2063-2066

10.1182/blood.2024025681 | PMID 39255410 Get It

Abstract Recent introduction of 2 different lymphoma classifications has raised concerns about consistency in diagnosis, management, and clinical trial enrollment. Data from a large cohort reflecting real-world clinical practice suggest that differences between the classifications will affect <1% of non-Hodgkin lymphomas.
Quality-of-life outcomes from NRG Oncology NSABP B-39/RTOG 0413: whole-breast irradiation vs accelerated partial-breast irradiation after breast-conserving surgery
Ganz, Patricia A. , Cecchini, Reena S. , White, Julia , Vicini, Frank A. , Arthur, Douglas W., Rabinovitch, Rachel , Kuske, Robert R. , Julian, Thomas B. , Parda, David S., Scheier, Michael F. , Winter, Kathryn, Paik, Soonmyung , Kuerer, Henry M. , Vallow, Laura A., Pierce, Lori J. , Mamounas, Eleftherios P. , Germain, Isabelle, Gustafson, Gregory S, Grossheim, Linda , Petersen, Ivy A. , Curran, Walter J. , White, Julia R , Hudes, Richard S , Wolmark, Norman , Mamounas, Eleftherios P. , McCormick, Beryl L. , Bear, Harry D. , Wolmark, Norman

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 10, 2024 | Volume: 117 | Issue: 1 | Pages: 103-111

10.1093/jnci/djae219 | PMID 39254630 Get It

Abstract Background NRG Oncology NSABP B-39/RTOG 0413 compared whole-breast irradiation (WBI) to accelerated partial-breast irradiation (APBI). APBI was not equivalent to WBI in local tumor control. Secondary outcome was quality of life (QOL). Methods The QOL sub-study used validated self-report questionnaires, including the Breast Cancer Treatment Outcome Scale (BCTOS) and the 36-Item Short Form Health Survey (SF-36) vitality scale. Assessments occurred before random assignment, at treatment completion (chemotherapy or radiotherapy), 4 weeks later, at 6, 12, 24, and 36 months. Primary aims: cosmesis change equivalency (baseline to 3 years; a priori margin of equivalence 0.4 standard deviations) and fatigue change superiority (baseline to end of treatment [EOT]) for APBI vs WBI, by patient groups treated with or without chemotherapy when appropriate. Results From March 21, 2005 to May 25, 2009, 975 patients enrolled in this sub-study; 950 had follow-up data. APBI had 3-year cosmesis equivalent to WBI (95% CI = -0.0001 to -0.16; equivalence margin -0.22 to -0.22) in all patients. The APBI group without chemotherapy had less EOT fatigue (P = .011; mean score APBI 63 vs WBI 59); the APBI group receiving chemotherapy had worse EOT fatigue (P = .011; APBI 43 vs WBI 49). The APBI group reported less pain (BCTOS) at EOT (WBI 2.29 vs APBI 1.97) but worse pain at 3 years (WBI 1.62 vs APBI 1.71). APBI patients reported greater convenience of care than with WBI and reported less symptom severity at EOT and 4 weeks later. Conclusion Cosmetic outcomes were similar for the APBI and WBI groups, with small statistically significant differences in other outcomes that varied over time. Differences in fatigue and other symptoms appeared to resolve by ≥6 months. APBI may be preferred by some patients, for whom extended treatment is burdensome. ClinicalTrials.gov NCT00103181.